Stock Events

Stock Events

Mineralys Therapeutics 

$28.1
0
+$0+0% Wednesday 04:36

Statistics

Day High
28.41
Day Low
28.06
52W High
-
52W Low
-
Volume
1,352
Avg. Volume
-
Mkt Cap
2.22B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MayExpected
Q3 2025
Q4 2025
Next
-0.61
-0.54
-0.47
-0.4
Expected EPS
-0.47585
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
0Revenue
-355.62MNet Income

Analyst Ratings

$53.50Average Price Target
The highest estimate is 56.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MLYS.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Ardelyx
ARDX
Mkt Cap1.47B
Ardelyx focuses on kidney and cardiovascular diseases, directly competing in the same therapeutic areas as Mineralys Therapeutics.
Aurinia Pharmaceuticals
AUPH
Mkt Cap1.73B
Aurinia Pharmaceuticals develops drugs for kidney diseases and lupus, overlapping with Mineralys' focus on renal health.
Trevena
TRVN
Mkt Cap10,365
Trevena, Inc. develops therapies for central nervous system disorders but has interests in expanding to other areas including treatments that could compete with Mineralys.
Akebia Therapeutics
AKBA
Mkt Cap585.97M
Akebia Therapeutics focuses on kidney disease and anemia, areas that overlap with Mineralys Therapeutics' interests.
Amarin
AMRN
Mkt Cap338.71M
Amarin Corporation focuses on cardiovascular health, which can be indirectly competitive with Mineralys' focus on conditions that affect the heart and kidneys.
Galmed Pharmaceuticals
GLMD
Mkt Cap7.51M
Galmed Pharmaceuticals works on liver diseases and metabolic disorders, which can intersect with Mineralys' therapeutic areas in terms of metabolic health and its impact on kidney function.

About

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Show more...
CEO
ISIN
US6031701013

Listings

XNAS
US
MLYS
BOATS
BOATS
MLYS.BOATS

0 Comments

Share your thoughts

FAQ

What is Mineralys Therapeutics stock price today?▼
The current price of MLYS.BOATS is $28.1 USD — it has increased by +0% in the past 24 hours. Watch Mineralys Therapeutics stock price performance more closely on the chart.
What is Mineralys Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Mineralys Therapeutics stocks are traded under the ticker MLYS.BOATS.
What is Mineralys Therapeutics market cap?▼
Today Mineralys Therapeutics has the market capitalization of 2.22B
When is the next Mineralys Therapeutics earnings date?▼
Mineralys Therapeutics is going to release the next earnings report on May 18, 2026.
What were Mineralys Therapeutics earnings last quarter?▼
MLYS.BOATS earnings for the last quarter are -0.4 USD per share, whereas the estimation was -0.52 USD resulting in a +22.52% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Mineralys Therapeutics revenue for the last year?▼
Mineralys Therapeutics revenue for the last year amounts to 0 USD.
What is Mineralys Therapeutics net income for the last year?▼
MLYS.BOATS net income for the last year is -355.62M USD.
When did Mineralys Therapeutics complete a stock split?▼
Mineralys Therapeutics has not had any recent stock splits.